The signaling function of IDO1 incites the malignant progression of mouse B16 melanoma

References

• Ernst M, Giubellino A. The current state of treatment and future directions in cutaneous malignant melanoma. Biomedicines. 2022 March;10(4):822. doi:10.3390/biomedicines10040822.
   PubMed Web of Science ®Google Scholar
• Olbryt M. Molecular background of skin melanoma development and progression: therapeutic implications. Postepy Dermatol Alergol. 2019;36(2):129–14. doi:10.5114/ada.2019.84590.
   PubMed Web of Science ®Google Scholar
• Kozyra P, Krasowska D, Pitucha M, Barresi V, Di Liberto V, Frinchi M, Bentivoglio M, Condorelli DF. New potential agents for malignant melanoma treatment-most recent studies 2020-2022. Int J Mol Sci. 2022;24(1):23. doi:10.3390/ijms24010023.
   PubMedGoogle Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654.
   PubMed Web of Science ®Google Scholar
• Paluncic J, Kovacevic Z, Jansson PJ, Kalinowski D, Merlot AM, Huang MLH, Lok HC, Sahni S, Lane DJR, Richardson DR, et al. Roads to melanoma: key pathways and emerging players in melanoma progression and oncogenic signaling. Biochim Biophys Acta. 2016;1863(4):770–784. doi:10.1016/j.bbamcr.2016.01.025.
   PubMed Web of Science ®Google Scholar
• Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007;445(7130):851–857. doi:10.1038/nature05661.
   PubMed Web of Science ®Google Scholar
• Eddy K, Shah R, Chen S. Decoding melanoma development and progression: identification of therapeutic vulnerabilities. Front Oncol. 2020;10:626129. doi:10.3389/fonc.2020.626129.
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355. doi:10.1126/science.aar4060.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen -T-T, Berman DM, Wolchok JD, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–1894. doi:10.1200/JCO.2014.56.2736.
   PubMed Web of Science ®Google Scholar
• Carretero-González A, Lora D, Ghanem I et al, Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials. Oncotarget. 2018;9: 8706–8715.
   PubMedGoogle Scholar
• Terness P, Bauer TM, Röse L, Dufter C, Watzlik A, Simon H, Opelz G. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med. 2002;196(4):447–457. doi:10.1084/jem.20020052.
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest. 2007;117(5):1147–1154. doi:10.1172/JCI31178.
   PubMed Web of Science ®Google Scholar
• Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol. 2010;185(6):3190–3198. doi:10.4049/jimmunol.0903670.
   PubMed Web of Science ®Google Scholar
• Platten M, Nollen EAA, Röhrig UF, Fallarino F, Opitz CA. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019;18(5):379–401. doi:10.1038/s41573-019-0016-5.
   PubMed Web of Science ®Google Scholar
• Gargaro M, Scalisi G, Manni G, Briseño CG, Bagadia P, Durai V, Theisen DJ, Kim S, Castelli M, Xu CA, et al. Indoleamine 2,3-dioxygenase 1 activation in mature cDC1 promotes tolerogenic education of inflammatory cDC2 via metabolic communication. Immunity. 2022;55(6):1032–1050.e1014. doi:10.1016/j.immuni.2022.05.013.
   PubMed Web of Science ®Google Scholar
• Long GV, Dummer R, Hamid O, Gajewski T, Caglevic C, Dalle S, Arance A, Carlino MS, Grob -J-J, Kim TM, et al. Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: results of the phase 3 ECHO-301/KEYNOTE-252 study. J Clin Oncol. 2018;36(15_suppl):108. doi:10.1200/JCO.2018.36.15_suppl.108.
   Web of Science ®Google Scholar
• Eynde B, Baren N, Baurain J-F. Is there a clinical future for IDO1 inhibitors after the failure of epacadostat in melanoma? Ann Rev Cancer Biol. 2020;4(1):241–256. doi:10.1146/annurev-cancerbio-030419-033635.
   Google Scholar
• Pallotta MT, Rossini S, Suvieri C, Coletti A, Orabona C, Macchiarulo A, Volpi C, Grohmann U. Indoleamine 2,3-dioxygenase 1 (IDO1): an up-to-date overview of an eclectic immunoregulatory enzyme. Febs J. 2021;289(20):6099–6118. doi:10.1111/febs.16086.
   PubMed Web of Science ®Google Scholar
• Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, Servillo G, Brunacci C, Calvitti M, Bicciato S, et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol. 2011;12(9):870–878. doi:10.1038/ni.2077.
   PubMed Web of Science ®Google Scholar
• Orabona C, Pallotta MT, Grohmann U. Different partners, opposite outcomes: a new perspective of the immunobiology of indoleamine 2,3-dioxygenase. Mol Med. 2012;18(5):834–842. doi:10.2119/molmed.2012.00029.
   PubMed Web of Science ®Google Scholar
• Orabona C, Pallotta MT, Volpi C, Fallarino F, Vacca C, Bianchi R, Belladonna ML, Fioretti MC, Grohmann U, Puccetti P, et al. SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci U S A. 2008;105(52):20828–20833. doi:10.1073/pnas.0810278105.
   PubMed Web of Science ®Google Scholar
• Albini E, Rosini V, Gargaro M, Mondanelli G, Belladonna ML, Pallotta MT, Volpi C, Fallarino F, Macchiarulo A, Antognelli C, et al. Distinct roles of immunoreceptor tyrosine-based motifs in immunosuppressive indoleamine 2,3-dioxygenase 1. J Cell Mol Med. 2017;21(1):165–176. doi:10.1111/jcmm.12954.
   PubMed Web of Science ®Google Scholar
• Thomas SR, Salahifar H, Mashima R, Hunt NH, Richardson DR, Stocker R. Antioxidants inhibit indoleamine 2,3-dioxygenase in IFN-gamma-activated human macrophages: posttranslational regulation by pyrrolidine dithiocarbamate. J Immunol. 2001;166(10):6332–6340. doi:10.4049/jimmunol.166.10.6332.
   PubMed Web of Science ®Google Scholar
• Nelp MT, Kates PA, Hunt JT, Newitt JA, Balog A, Maley D, Zhu X, Abell L, Allentoff A, Borzilleri R, et al. Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form. Proc Natl Acad Sci U S A. 2018;115(13):3249–3254. doi:10.1073/pnas.1719190115.
   PubMed Web of Science ®Google Scholar
• Zhai L, Ladomersky E, Dostal CR, Lauing KL, Swoap K, Billingham LK, Gritsina G, Wu M, McCusker RH, Binder DC, et al. Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma. Brain Behav Immun. 2017;62:24–29. doi:10.1016/j.bbi.2017.01.022.
   PubMed Web of Science ®Google Scholar
• Zhai L, Bell A, Ladomersky E, Lauing KL, Bollu L, Nguyen B, Genet M, Kim M, Chen P, Mi X, et al. Tumor cell IDO enhances immune suppression and decreases survival independent of tryptophan metabolism in glioblastoma. Clin Cancer Res. 2021;27(23):6514–6528. doi:10.1158/1078-0432.CCR-21-1392.
   PubMed Web of Science ®Google Scholar
• Ladomersky E, Zhai L, Lauing KL, Bell A, Xu J, Kocherginsky M, Zhang B, Wu JD, Podojil JR, Platanias LC, et al. Advanced age increases immunosuppression in the brain and decreases immunotherapeutic efficacy in subjects with glioblastoma. Clin Cancer Res. 2020;26(19):5232–5245. doi:10.1158/1078-0432.CCR-19-3874.
   PubMed Web of Science ®Google Scholar
• Sun L. Advances in the discovery and development of selective heme-displacing IDO1 inhibitors. Expert Opin Drug Discov. 2020;15(10):1223–1232. doi:10.1080/17460441.2020.1781811.
   PubMed Web of Science ®Google Scholar
• Mondanelli G, Bianchi R, Pallotta MT, Orabona C, Albini E, Iacono A, Belladonna ML, Vacca C, Fallarino F, Macchiarulo A, et al. A relay pathway between arginine and tryptophan metabolism confers immunosuppressive properties on dendritic cells. Immunity. 2017;46(2):233–244. doi:10.1016/j.immuni.2017.01.005.
   PubMed Web of Science ®Google Scholar
• Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med. 2013;210(7):1389–1402. doi:10.1084/jem.20130066.
   PubMed Web of Science ®Google Scholar
• Albini E, Coletti A, Greco F, Pallotta MT, Mondanelli G, Gargaro M, Belladonna ML, Volpi C, Bianchi R, Grohmann U, et al. Identification of a 2-propanol analogue modulating the non-enzymatic function of indoleamine 2,3-dioxygenase 1. Biochem Pharmacol. 2018;158:286–297. doi:10.1016/j.bcp.2018.10.033.
   PubMed Web of Science ®Google Scholar
• Volpi C, Mondanelli G, Pallotta MT, Vacca C, Iacono A, Gargaro M, Albini E, Bianchi R, Belladonna ML, Celanire S, et al. Allosteric modulation of metabotropic glutamate receptor 4 activates IDO1-dependent, immunoregulatory signaling in dendritic cells. Neuropharmacology. 2016;102:59–71. doi:10.1016/j.neuropharm.2015.10.036.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang F, Niu R. Functions of Shp2 in cancer. J Cell Mol Med. 2015;19(9):2075–2083. doi:10.1111/jcmm.12618.
   PubMed Web of Science ®Google Scholar
• Grossmann KS, Rosário M, Birchmeier C, Birchmeier W. The tyrosine phosphatase Shp2 in development and cancer. Adv Cancer Res. 2010;106:53–89.
   PubMed Web of Science ®Google Scholar
• Zhang RY, Yu ZH, Zeng L, Zhang S, Bai Y, Miao J, Chen L, Xie J, Zhang Z-Y. SHP2 phosphatase as a novel therapeutic target for melanoma treatment. Oncotarget. 2016;7(45):73817–73829. doi:10.18632/oncotarget.12074.
   PubMedGoogle Scholar
• Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(1):103–119. doi:10.1517/14728222.2011.645805.
   PubMed Web of Science ®Google Scholar
• Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee M-K, Attar N, Sazegar H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973–977. doi:10.1038/nature09626.
   PubMed Web of Science ®Google Scholar
• Théate I, van Baren N, Pilotte L, Moulin P, Larrieu P, Renauld J-C, Hervé C, Gutierrez-Roelens I, Marbaix E, Sempoux C, et al. Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues. Cancer Immunol Res. 2015;3(2):161–172. doi:10.1158/2326-6066.CIR-14-0137.
   PubMed Web of Science ®Google Scholar
• Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9(10):1269–1274. doi:10.1038/nm934.
   PubMed Web of Science ®Google Scholar
• Feng X, Liao D, Liu D, Ping A, Li Z, Bian J. Development of Indoleamine 2,3-Dioxygenase 1 inhibitors for cancer therapy and beyond: a recent perspective. J Med Chem. 2020;63(24):15115–15139. doi:10.1021/acs.jmedchem.0c00925.
   PubMed Web of Science ®Google Scholar
• Liu W, Zou Y, Li K, Zhong H, Yu L, Ge S, Lai Y, Dong X, Xu Q, Guo W, et al. Apo-form selective inhibition of IDO for tumor immunotherapy. J Immunol. 2022;209(1):180–191. doi:10.4049/jimmunol.2100938.
   PubMed Web of Science ®Google Scholar
• Biswas P, Dai Y, Stuehr DJ. Indoleamine dioxygenase and tryptophan dioxygenase activities are regulated through GAPDH- and Hsp90-dependent control of their heme levels. Free Radic Biol Med. 2022;180:179–190. doi:10.1016/j.freeradbiomed.2022.01.008.
   PubMed Web of Science ®Google Scholar
• Mondanelli G, Albini E, Pallotta MT, Volpi C, Chatenoud L, Kuhn C, Fallarino F, Matino D, Belladonna ML, Bianchi R, et al. The proteasome inhibitor bortezomib controls indoleamine 2,3-Dioxygenase 1 breakdown and restores immune regulation in autoimmune diabetes. Front Immunol. 2017;8:428. doi:10.3389/fimmu.2017.00428.
   PubMed Web of Science ®Google Scholar
• Mondanelli G, Di Battista V, Pellanera F, Mammoli A, Macchiarulo A, Gargaro M, Mavridou E, Matteucci C, Ruggeri L, Orabona C, et al. A novel mutation of indoleamine 2,3-dioxygenase 1 causes a rapid proteasomal degradation and compromises protein function. J Autoimmun. 2020;115:102509. doi:10.1016/j.jaut.2020.102509.
   PubMed Web of Science ®Google Scholar
• Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn D, Allison J, Merghoub T, Wolchok J. Tumor-expressed IDO recruits and activates MDSCs in a treg-dependent manner. Cell Rep. 2015;13(2):412–424. doi:10.1016/j.celrep.2015.08.077.
   PubMed Web of Science ®Google Scholar
• Bartok O, Pataskar A, Nagel R, Laos M, Goldfarb E, Hayoun D, Levy R, Körner P-R, Kreuger IZM, Champagne J, et al. Anti-tumour immunity induces aberrant peptide presentation in melanoma. Nature. 2021;590(7845):332–337. doi:10.1038/s41586-020-03054-1.
   PubMedGoogle Scholar
• Zhai L, Bell A, Ladomersky E, Lauing KL, Bollu L, Sosman JA, Zhang B, Wu JD, Miller SD, Meeks JJ, et al. Immunosuppressive IDO in cancer: mechanisms of action, animal models, and targeting strategies. Front Immunol. 2020;11:1185. doi:10.3389/fimmu.2020.01185.
   PubMed Web of Science ®Google Scholar
• Campesato LF, Budhu S, Tchaicha J, Weng C-H, Gigoux M, Cohen IJ, Redmond D, Mangarin L, Pourpe S, Liu C, et al. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nat Commun. 2020;11(1):4011. doi:10.1038/s41467-020-17750-z.
   PubMed Web of Science ®Google Scholar
• Atene CG, Fiorcari S, Mesini N, Alboni S, Martinelli S, Maccaferri M, Leonardi G, Potenza L, Luppi M, Maffei R, et al. Indoleamine 2, 3-Dioxygenase 1 mediates survival signals in chronic lymphocytic leukemia via kynurenine/aryl hydrocarbon receptor-mediated MCL1 modulation. Front Immunol. 2022;13:832263. doi:10.3389/fimmu.2022.832263.
   PubMed Web of Science ®Google Scholar
• Bollu LR, Bommi PV, Monsen PJ, Zhai L, Lauing KL, Bell A, Kim M, Ladomersky E, Yang X, Platanias LC, et al. Identification and characterization of a novel indoleamine 2,3-Dioxygenase 1 protein degrader for glioblastoma. J Med Chem. 2022;65(23):15642–15662. doi:10.1021/acs.jmedchem.2c00771.
   PubMed Web of Science ®Google Scholar